Ireland
--:--IST
Active, not recruiting Not applicable

Portico Next Generation Approval Study

NCT04011722 · tracked via the Priya Life Science USA tracker
Phase
Not applicable
Started
2019-09-17
Last updated
2026-11-17

Condition(s) studied

Symptomatic Severe Aortic Stenosis

Investigational drug(s) / intervention(s)

Portico™ NG (Navitor) Valve and FlexNav™ Delivery SystemNavitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System

Portico™ NG (Navitor) Valve and FlexNav™ Delivery System: Subjects will undergo transcatheter aortic valve implantation (TAVI) with the new generation Portico NG (Navitor) valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.

Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System: Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor Titan valve and large FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.

Study summary

The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days in a high or extreme surgical risk patient population to support CE (Conformité Européenne) Mark and FDA approval.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Key Inclusion Criteria: 1. Subjects must have a Society of Thoracic Surgeons (STS) score of ≥7% OR documented heart team agreement of high or extreme risk for surgical aortic valve replacement due to frailty or co-morbidities not captured by the STS score. 2. Subject has symptomatic aortic stenosis as demonstrated by NYHA (New York Heart Association) Functional Classification of II, III, or IV. 3. Subject has senile degenerative aortic valve stenosis with echo-derived criteria, defined as: aortic valve area (AVA) of ≤ 1.0 cm2 (or indexed EOA (effective orifice area) ≤ 0.6 cm2/m2) AND mean gradient ≥40 mmHg or peak jet velocity ≥ 4.0 m/s or doppler velocity index (DVI) ≤0.25. (Qualifying AVA baseline measurement must be within 90 days prior to informed consent). 4. Aortic annulus diameter of 19-30mm and ascending aorta diameter for the specified valve size listed in the IFU (Instructions For Use), as measured by CT (Computed Tomography) Key Exclusion Criteria: 1. Evidence of an acute myocardial infarction (defined as: ST Segment Elevation as evidenced on 12 Lead ECG) within 30 days prior to index procedure. 2. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to index procedure. 3. Blood dyscrasias as defined: leukopenia (WBC\<3000 mm3), acute anemia (Hb \< 9 g/dL), thrombocytopenia (platelet count \<50,000 cells/mm³). History of bleeding diathesis or coagulopathy 4. Active peptic ulcer or upper GI bleeding within 3 months prior to index procedure that would preclude anticoagulation 5. Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA) or a transient ischemic attack (TIA). 6. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation 3-4+). 7. Pre-existing prosthetic heart valve or other implant in any valve position, prosthetic ring, severe circumferential mitral annular calcification (MAC) which is continuous with calcium in the left ventricular outflow tract (LVOT), severe (greater than or equal to 3+) mitral insufficiency, or severe mitral stenosis with pulmonary compromise. 8. Minimum access vessel diameter of \<5.0mm for small FlexNav™ Delivery System and \<5.5 mm for large FlexNav™ Delivery System

Primary outcome measure(s)

  • Primary Safety Endpoint is All-cause Mortality — at 30 days
    All-cause mortality is defined as the total number of deaths in each cohort at 30 days.
  • Primary Effectiveness Endpoint is Moderate or Greater Paravalvular Leak — at 30 days
    Number of participants with moderate or greater paravalvular leak at 30 days.

Trial sites (28)

FacilityCityRegionStatus
Cedars-Sinai Medical Center Los Angeles California
Los Robles Regional Medical Center Thousand Oaks California
MedStar Washington Hospital Center Washington D.C. District of Columbia
Advocate Christ Medical Center Oak Lawn Illinois
Ascension St. Vincent Indianapolis Indiana
Ascension Via Christi Hospitals Wichita Wichita Kansas
Sparrow Clinical Research Institute Lansing Michigan
Minneapolis Heart Institute Foundation Minneapolis Minnesota
Morristown Medical Center Morristown New Jersey
Albany Medical Center Albany New York
Columbia Univ. Medical Center/NewYork-Presbyterian Hospital New York New York
Montefiore Medical Center - Moses Campus New York New York
Mission Hospital Asheville North Carolina
University Hospitals Cleveland Medical Center Cleveland Ohio
Providence St. Vincent Medical Center Portland Oregon
UPMC Pittsburgh Pennsylvania
Baptist Memorial Hospital Memphis Tennessee
Houston Methodist Houston Texas
Baylor Scott & White - The Heart Hospital Plano Plano Texas
Intermountain St. George Regional Hospital St. George Utah
Sentara Norfolk General Hospital Norfolk Virginia
St. Andrew's Hospital Adelaide South Australia
The Alfred Hospital Melbourne Victoria
Fiona Stanley Hospital Murdoch Western Australia
Rigshospitalet Copenhagen Denmark
Policlinico San Donato San Donato Milanese Lombard
Royal Victoria Hospital Belfast Northern Ireland
Morriston Hospital - ABM University Health Board Morriston SWANSEA

More Abbott Medical Devices trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04011722 on ClinicalTrials.gov ↗ ← All trials in the USA